Using a Risk Score Calculator to Predict Survival Rates

2018-10-12T21:31:14+00:00 October 12th, 2018|

by Phyllis Hanlon, Contributing Writer The Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL registry) is a study of approximately 3,500 people with World Health Organization (WHO) Group 1 pulmonary hypertension (pulmonary arterial hypertension, or PAH) in the U.S. Study participants who were followed 2006-2011 contributed important information to the pulmonary hypertension (PH)

The DIBOSA Study: The 6MWT Helps Predict PH in Patients with SSc

2018-10-05T20:46:46+00:00 October 5th, 2018|

by Phyllis Hanlon, Contributing Writer Research has found that World Health Organization (WHO) Group 1 pulmonary hypertension (PH) (pulmonary arterial hypertension, or PAH) affects 8 to 12 percent of patients who have systemic sclerosis (SSc, a form of scleroderma – a disease that causes hardening and tightening of the skin and connective tissues) and

Results of Portopulmonary Hypertension Trial Released at European Respiratory Society Meeting

2018-09-28T16:35:32+00:00 September 28th, 2018|

Actelion Pharmaceuticals Ltd. has announced the results of the first randomized controlled trial in portopulmonary hypertension (PoPH), which showed that macitentan (Opsumit®) significantly improved pulmonary vascular resistance (PVR) compared with a placebo. Macitentan is currently approved for the treatment of pulmonary arterial hypertension (PAH). Presented as a late-breaking oral presentation at the European Respiratory

Analyzing the Effects of PH in Patients with Kidney Disease

2018-09-21T20:51:33+00:00 September 21st, 2018|

by Phyllis Hanlon, Contributing Writer According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) approximately 14 percent of the general population has chronic kidney disease (CKD); more than 661,000 Americans have kidney failure and 468,000 of these are on dialysis. Furthermore, CKD often occurs along with other medical conditions, earning the

Treating PH: Joint Symposium Discusses Options

2018-09-07T20:04:55+00:00 September 7th, 2018|

by Phyllis Hanlon, Contributing Writer Although there are 14 different Food and Drug Administration (FDA)-approved therapies for treating World Health Organization (WHO) Group 1 pulmonary hypertension (PH) (pulmonary arterial hypertension, or PAH), there remains a need for treatments that can be used across varying classifications of PH. In 2017, the Critical Care Medicine Department of

Examination of PHAR Data Shows Few Patients are Referred to Palliative Care

2018-08-31T15:42:34+00:00 August 31st, 2018|

Although treatment options for WHO Group 1 PH (pulmonary arterial hypertension, or PAH) have increased over the past few decades, symptom severity and quality of life still impose significant burden on patients. Palliative care – often confused with hospice care – is goal-oriented care for patients with chronic illnesses that help to balance life-saving

PHA Weighs in With FDA on Patient Engagement

2018-08-24T16:22:02+00:00 August 24th, 2018|

The Food and Drug Administration (FDA) is drafting guidelines related to patient engagement in the clinical trials process and the Pulmonary Hypertension Association (PHA) is weighing in. Recently, the FDA announced that it will produce a four-part document, “Patient-Focused Drug Development: Collecting Comprehensive and Representative Input; Guidance for Industry, Food and Drug Administration Staff, and

Bellerophon Therapeutics Announces Interim Results of Nitric Oxide Clinical Trial in Pulmonary Arterial Hypertension

2018-08-10T21:02:47+00:00 August 10th, 2018|

Bellerophon Therapeutics announced this week that its Phase 3 clinical trial of pulsatile inhaled nitric oxide (iNO) for World Health Organization (WHO) Group 1 PH (pulmonary arterial hypertension, or PAH) was discontinued for futility August 7, after a planned interim analysis. Nitric oxide (NO) is a molecule naturally produced in the body that helps many

Fatigue: Under-Recognized and Unaddressed in PH

2018-08-10T21:01:47+00:00 August 10th, 2018|

by Phyllis Hanlon, Contributing Writer Symptoms that are commonly experienced by people with pulmonary hypertension (PH) — such as shortness of breath, light-headedness, chest pain, swelling and fatigue — can negatively impact their quality of life. Fatigue – lack of energy or an increased sense of effort with routine tasks – is reported in

Participation in PHA Conference Opens Doors for Northwestern University Researcher

2018-07-27T17:41:33+00:00 July 27th, 2018|

Zhiyu Dai, Ph.D., a researcher at Northwestern University and assistant professor of research at Northwestern University Feinberg School of Medicine in Chicago, has presented his work during the past two Pulmonary Hypertension Association (PHA) International PH Conference and Scientific Sessions. He also has been awarded top abstract in basic science by the Scientific Sessions